Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Safety in clinical trials

Safety reporting timelines and oversight committees

12 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Describe expedited reporting of SUSARs and annual safety reports

  • Explain the role of a data safety monitoring board

  • Describe what happens when a safety signal emerges

Safety reporting involves several parties, each with duties and deadlines.

Who reports what, and when

  • Investigator to sponsor: all SAEs immediately, typically within 24 hours of awareness, with a full follow-up report.
  • Sponsor to regulators and ethics committees: SUSARs are reported on an expedited basis. In ICH-based systems the usual standard is 7 calendar days for fatal or life-threatening SUSARs (with follow-up information within a further 8 days) and 15 calendar days for other SUSARs. Local rules differ, so always check the requirements of each regulator and ethics committee.
  • Sponsor to investigators: safety information that affects the study, including updated investigator brochures and urgent safety measures.
  • Periodic reports: an annual safety report (such as the Development Safety Update Report, DSUR) summarises safety data across the programme, and ethics committees receive annual progress reports.
  • Urgent safety measures: immediate action to protect participants from a hazard may be taken before approval and then notified.
Day 0Event becomes knownDay 1Investigator reportsSAEDay 7Fatal SUSAR reportedDay 15Other SUSARs reported
Typical expedited reporting clocks. Check local rules and sponsor procedures.

Data safety monitoring boards

A data and safety monitoring board (DSMB, or DMC) is an independent group of experts, often including clinicians, a statistician and an ethicist, that reviews accumulating unblinded data to protect participants and the trial's integrity.

  • It reviews safety, and sometimes efficacy, at pre-planned intervals.
  • It can recommend that the trial continue unchanged, be modified, be paused or be stopped for harm, clear benefit or futility.
  • Its recommendations go to the sponsor, which makes the final decision.
  • Members must be independent of the sponsor and investigators.
  • Its work is governed by a charter that sets out membership, meeting schedule, confidentiality and decision rules.

Safety signals and stopping rules

A safety signal is information suggesting a new or changed risk. The sponsor and DSMB assess signals using cumulative data, comparing event rates between arms. Protocols often define stopping or pausing rules, such as pausing enrolment if two participants have the same severe reaction in a short period.

Worked example: pausing for a safety signal

In a vaccine trial, two of the first 60 participants have a severe allergic reaction within an hour of vaccination.

  • The investigators report both as SAEs within 24 hours.
  • The sponsor assesses them as possibly related and not listed, so they are SUSARs, reported to regulators and ethics committees within the required days.
  • The protocol's rule says to pause dosing if two similar severe reactions occur within the first 100 participants. The sponsor pauses.
  • The DSMB meets within a week, reviews unblinded data, and finds the reactions occurred after the vaccine, not placebo. It recommends adding a 30-minute observation period and resuming.
  • The regulator and ethics committees approve the amendment, sites are retrained, and dosing resumes.

Clear rules, fast reporting and independent review protected participants.

1SignalEvents or labpattern2AssessSponsor and DSMB3ActPause, amend, orstop4NotifyRegulators andethics5Resume orcloseWith newsafeguards
Handling a safety signal.

Independence is the point

The DSMB can see unblinded results so that the sponsor and sites stay blinded. This protects trial integrity while keeping participants safe.

Late reports weaken oversight

Delays in reporting SAEs delay decisions that might protect other participants. Treat each reporting clock as a hard deadline.

Check yourself

Write the reporting chain for an SAE in your trial: who is told first, and by when, and how will the site confirm it was sent?

Summary

  • Investigators report SAEs to the sponsor within about 24 hours; sponsors report SUSARs to regulators and ethics committees on expedited timelines.

  • Fatal or life-threatening SUSARs usually 7 days (plus follow-up), others 15 days under ICH-based systems.

  • A DSMB independently reviews unblinded data and advises continuing, modifying, pausing or stopping.

  • Protocols define stopping and pausing rules for safety signals.

Check your understanding

Question 1
1

A DSMB is:

Question 2
2

In ICH-based systems, a fatal SUSAR is generally reported to regulators within:

Question 3
3

The final decision to continue, modify or stop a trial rests with the:

Question 4
4

A safety signal is:

Question 5
5

An urgent safety measure allows:

Question 6
6

The DSMB charter defines:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Adverse events and serious adverse eventsPharmacovigilance and risk management